Ann: 200th patient treated with the OncoSil device, page-48

It appears after the presentation that Oncosil is engaged in a multi play growth strategy:-

(1) Obtain regulatory approval from the EU MDR, FDA (US) & TGA (Aus) & GBA (Germany).

(2) Expand label use with clinic trials to extend cover to Folforinix chemo combination (Tripp FFX trial) and percutaneous (Pancosil trial).

(3) Expansion of commercial sales via expanded footprint & commercial agreements for new jurisdictions & new hospital adoptions: Spain, Italy, Saudi Arabia Turkey & South Korea.

(4) Possible new strategic partnerships or even mergers/acquisition activities.

(5) Recommence sales in NZ and begin new sales in Hong Kong & China Bay & UK.


Major, not even $20 million market cap for all of this. At 0.005, it’s capped at $16 million with $7-$9 million cash. So, an EV that of circa $7 million. Let me repeat an EV of only $7 million.